Evamist Shortage: What Providers and Prescribers Need to Know in 2026

Evamist (estradiol transdermal spray, 1.53 mg/spray) is the only FDA-approved transdermal estradiol spray. Manufactured by Padagis, it was relaunched in 2022 after years off the market. While Evamist remains technically available and is not on the FDA's official shortage database, your patients are increasingly reporting that their pharmacies either don't stock it or are temporarily out. This guide provides the clinical context providers need to manage this situation effectively.

Why Are Patients Having Trouble Filling Evamist Prescriptions?

Evamist's availability challenges stem from several converging factors in the current HRT supply environment:

Demand surge from estradiol patch shortage: Widespread shortages of estradiol transdermal patches (Vivelle-Dot, Climara, Lyllana, and generics) have redirected prescribers toward alternative transdermal options. Evamist is frequently cited as a first-line alternative, driving new demand onto a product with historically limited pharmacy inventory.

Post-black box warning removal surge: The FDA removed the black box warning from bioidentical estradiol products in late 2025, resulting in a measurable increase in new HRT prescriptions. This has amplified demand across all estrogen formulations simultaneously.

No generic substitution available: Because no generic estradiol transdermal spray exists, pharmacists have no substitution option when Evamist stock runs out. Every prescription requires Padagis product.

Thin baseline pharmacy stocking: Many retail pharmacies did not add Evamist back to standard formulary after its 2022 relaunch, given the small legacy patient base. Independent and specialty pharmacies are better positioned to source it.

Prescribing Strategies to Improve Fill Rates

Several prescription-writing strategies can improve your patient's chances of filling their Evamist script:

Direct to specialty or independent pharmacies: Evamist is more reliably stocked at independent community pharmacies and specialty mail-order pharmacies than at national chains. Consider asking patients to call ahead or noting a preferred pharmacy on the prescription.

Recommend mail-order: Amazon Pharmacy, Express Scripts, Optum Rx, and similar services often have more reliable supply chains for specialty HRT products. A 90-day supply also reduces refill frequency.

Authorize early refills: A note on the prescription authorizing early refills ("may refill 7 days early") can help patients avoid running out while searching for a stocked pharmacy.

Direct patients to medfinder:medfinder.com allows patients to provide their medication and location, then calls nearby pharmacies to check stock, delivering results by text. This eliminates the logistical burden on patients.

Clinically Appropriate Alternatives When Evamist Is Unavailable

When Evamist is consistently unavailable, consider these alternatives based on patient-specific factors:

EstroGel (estradiol 0.06% gel) or Divigel: Closest functional equivalents. Transdermal estradiol applied to skin daily. Widely available. Appropriate for all patients who would be candidates for Evamist.

Estradiol transdermal patches: If available, patches (1-2x weekly) are another transdermal option. Note that patches are experiencing their own supply challenges. Confirm pharmacy availability before switching.

Oral estradiol (generic): Widely available and affordable. Appropriate for many patients, but note higher VTE risk vs. transdermal in patients with thrombosis risk factors, obesity, or smokers over 35.

Veozah (fezolinetant): For patients with contraindications to estrogen (hormone-sensitive cancer history, active thromboembolic disease, liver disease). The only FDA-approved non-hormonal VMS treatment acting on neurokinin B receptors.

Insurance and Prior Authorization Considerations

Evamist is covered by many commercial insurance plans and some Medicare plans, but prior authorization may be required. If a patient is being forced onto a higher-cost alternative due to Evamist unavailability, a letter of medical necessity citing the supply disruption can support prior authorization requests for alternatives that may have higher tier placement.

The Evamist Patient Savings Program, administered by Padagis, allows commercially insured patients to pay as little as $25 per prescription (maximum savings of $70/fill), and cash-paying patients can save up to $70 per prescription. Your patients can call 1-844-415-0672 or visit evamist.com for details.

Communicating With Patients About Availability

When prescribing Evamist, proactively inform patients that not all pharmacies stock it and that they may need to check multiple locations or use mail order. Direct them to medfinder for providers or to the Evamist shortage patient guide. Setting realistic expectations upfront reduces patient frustration and prevents treatment interruption.